Hypha Labs Files 8-K: Material Agreement, Equity Sales
Ticker: FUNI · Form: 8-K · Filed: Dec 16, 2024 · CIK: 1502966
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-action
TL;DR
Hypha Labs signed a big deal, sold some stock, and had a shareholder vote. Check the financials.
AI Summary
Hypha Labs, Inc. (formerly Digipath, Inc.) entered into a material definitive agreement on December 10, 2024. The company also reported on unregistered sales of equity securities and matters submitted to a vote of security holders. The filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions by Hypha Labs, including a new material agreement and equity transactions, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing details material agreements and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Hypha Labs, Inc. (company) — Registrant
- Digipath, Inc. (company) — Former Company Name
- December 10, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Hypha Labs, Inc.?
The filing states that Hypha Labs, Inc. entered into a material definitive agreement on December 10, 2024, but the specific details of this agreement are not provided in the excerpt.
What were the previous names of Hypha Labs, Inc.?
Hypha Labs, Inc. was formerly known as Digipath, Inc. and DigiPath,Inc.
When was the company incorporated or organized?
The company was incorporated or organized in Nevada.
What is the fiscal year end for Hypha Labs, Inc.?
The fiscal year end for Hypha Labs, Inc. is September 30.
What are the main items reported in this 8-K filing?
This 8-K filing reports on the entry into a material definitive agreement, unregistered sales of equity securities, submission of matters to a vote of security holders, and financial statements and exhibits.
Filing Stats: 1,037 words · 4 min read · ~3 pages · Grade level 11.4 · Accepted 2024-12-16 14:47:24
Key Financial Figures
- $0.10 — eferred Stock") for a purchase price of $0.10 per share of Series C Preferred Stock.
Filing Documents
- form8-k.htm (8-K) — 41KB
- ex10-1.htm (EX-10.1) — 21KB
- 0001493152-24-050186.txt ( ) — 233KB
- funi-20241210.xsd (EX-101.SCH) — 3KB
- funi-20241210_lab.xml (EX-101.LAB) — 33KB
- funi-20241210_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Hypha Labs, Inc. Date: December 16, 2024 By: /s/ A. Stone Douglass A. Stone Douglass Chairman, President, Chief Executive Officer, Chief Financial Officer and Secretary